Lawrence Leung

Publications

• Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage. Yamaguchi Y, Shao Z, Sharif S, Du XY, Myles T, Merchant M, Harsh G, Glantz M, Recht L, Morser J, Leung LL. J Biol Chem. 2013; 288 (5): 3097-111
• Chemerin158K protein is the dominant chemerin isoform in synovial and cerebrospinal fluids but not in plasma. Zhao L, Yamaguchi Y, Sharif S, Du XY, Song JJ, Lee DM, Recht LD, Robinson WH, Morser J, Leung LL. J Biol Chem. 2011; 286 (45): 39520-7
• Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. Song JJ, Hwang I, Cho KH, Garcia MA, Kim AJ, Wang TH, Lindstrom TM, Lee AT, Nishimura T, Zhao L, Morser J, Nesheim M, Goodman SB, Lee DM, Bridges SL, Gregersen PK, Leung LL, Robinson WH. J Clin Invest. 2011; 121 (9): 3517-27
• Proteolytic cleavage of chemerin protein is necessary for activation to the active form, Chem157S, which functions as a signaling molecule in glioblastoma. Yamaguchi Y, Du XY, Zhao L, Morser J, Leung LL. J Biol Chem. 2011; 286 (45): 39510-9
• Enhanced abdominal aortic aneurysm formation in thrombin-activatable procarboxypeptidase B-deficient mice. Schultz G, Tedesco MM, Sho E, Nishimura T, Sharif S, Du X, Myles T, Morser J, Dalman RL, Leung LL. Arterioscler Thromb Vasc Biol. 2010; 30 (7): 1363-70
• Heparin-induced thrombosis without thrombocytopenia. Tibayan FA, Leung LL, Burdon TA, Fann JI. J Thorac Cardiovasc Surg. 2010; 139 (2): e6-7
• What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse? Morser J, Gabazza EC, Myles T, Leung LL. J Thromb Haemost. 2010; 8 (5): 868-76
• Proteolytic regulatory mechanism of chemerin bioactivity. Du XY, Leung LL. Acta Biochim Biophys Sin (Shanghai). 2009; 41 (12): 973-9
• Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets. Du XY, Zabel BA, Myles T, Allen SJ, Handel TM, Lee PP, Butcher EC, Leung LL. J Biol Chem. 2009; 284 (2): 751-8
• Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis. Sharif SA, Du X, Myles T, Song JJ, Price E, Lee DM, Goodman SB, Nagashima M, Morser J, Robinson WH, Leung LL. Arthritis Rheum. 2009; 60 (10): 2902-12
• Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Leung LL, Nishimura T, Myles T. Adv Exp Med Biol. 2008: 632 61-9
• Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Leung LL, Myles T, Nishimura T, Song JJ, Robinson WH. Mol Immunol. 2008; 45 (16): 4080-3
• Thrombin hydrolysis of human osteopontin is dependent on thrombin anion-binding exosites. Myles T, Leung LL. J Biol Chem. 2008; 283 (26): 17789-96
• Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina? Itakura H, Sobel BE, Boothroyd D, Leung LL, Iribarren C, Go AS, Fortmann SP, Quertermous T, Hlatky MA. Am Heart J. 2007; 154 (6): 1059-64
• Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo. Nishimura T, Myles T, Piliponsky AM, Piliposky AM, Kao PN, Berry GJ, Leung LL. Blood. 2007; 109 (5): 1992-7
• Perioperative evaluation of bleeding diathesis. Leung LL, Hematology Am Soc Hematol Educ Program. 2006: 457-61
• Crystal structure of anticoagulant thrombin variant E217K provides insights into thrombin allostery. Carter WJ, Myles T, Gibbs CS, Leung LL, Huntington JA. J Biol Chem. 2004; 279 (25): 26387-94
• Molecular cloning of nonsecreted endothelial cell-derived lipase isoforms. Ishida T, Zheng Z, Dichek HL, Wang H, Moreno I, Yang E, Kundu RK, Talbi S, Hirata K, Leung LL, Quertermous T. Genomics. 2004; 83 (1): 24-33
• Molecular mapping of the thrombin-heparin cofactor II complex. Fortenberry YM, Whinna HC, Gentry HR, Myles T, Leung LL, Church FC. J Biol Chem. 2004; 279 (41): 43237-44
• Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, Pearl RG, Leung LL. J Biol Chem. 2003; 278 (51): 51059-67
• Thrombin activation of factor XI on activated platelets requires the interaction of factor XI and platelet glycoprotein Ib alpha with thrombin anion-binding exosites I and II, respectively. Yun TH, Baglia FA, Myles T, Navaneetham D, López JA, Walsh PN, Leung LL. J Biol Chem. 2003; 278 (48): 48112-9
• Structural requirements for the activation of human factor VIII by thrombin. Myles T, Yun TH, Leung LL. Blood. 2002; 100 (8): 2820-6
• An extensive interaction interface between thrombin and factor V is required for factor V activation. Myles T, Yun TH, Hall SW, Leung LL. J Biol Chem. 2001; 276 (27): 25143-9
• Identification of critical residues on thrombin mediating its interaction with fibrin. Hall SW, Gibbs CS, Leung LL. Thromb Haemost. 2001; 86 (6): 1466-74
• Dissociation of thrombin's substrate interactions using site-directed mutagenesis. Leung LL, Hall SW. Trends Cardiovasc Med. 2000; 10 (2): 89-92
• Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains. Hall SW, Nagashima M, Zhao L, Morser J, Leung LL. J Biol Chem. 1999; 274 (36): 25510-6
• A woman who had a stroke, then a myocardial infarction. Ciesielski-Carlucci C, Lee BK, Boxer LM, Leung LL. Lancet. 1997; 349 (9060): 1218
• Modulation of thrombin's procoagulant and anticoagulant properties. Leung LL, Gibbs CS. Thromb Haemost. 1997; 78 (1): 577-80
• Strategies for development of novel antithrombotics: modulating thrombin's procoagulant and anticoagulant properties. Hall SW, Gibbs CS, Leung LL. Cell Mol Life Sci. 1997; 53 (9): 731-6
• Application of combinatorial libraries and protein engineering to the discovery of novel anti-thrombotic drugs. Leung LL, Thromb Haemost. 1995; 74 (1): 373-6
• Conversion of thrombin into an anticoagulant by protein engineering Leung LLK, Gibbs CS, Coutre SE, Tsiang M, Li WX, Jain AK, Dunn KE, Law VS, Mao CT, Matsumura SY, Mejsa SJ, Paborsky LR,. Nature. 1995
• Functional mapping of the surface residues of human thrombin. Tsiang M, Jain AK, Dunn KE, Rojas ME, Leung LL, Gibbs CS. J Biol Chem. 1995; 270 (28): 16854-63
• Involvement of CD31 in lymphocyte-mediated immune responses: importance of the membrane-proximal immunoglobulin domain and identification of an inhibiting CD31 peptide. Zehnder JL, Shatsky M, Leung LL, Butcher EC, McGregor JL, Levitt LJ. Blood. 1995; 85 (5): 1282-8
• Selection of a suppressor mutation that restores affinity of an oligonucleotide inhibitor for thrombin using in vitro genetics. Tsiang M, Gibbs CS, Griffin LC, Dunn KE, Leung LL. J Biol Chem. 1995; 270 (33): 19370-6
• Identification of SVTCG as the conformation-dependent high affinity binding site in thrombospondin for its ligand CD36 Leung LLK., Li WX, Kaplan AV, Grant GW, Toole JJ,. J. Biol. Chem. 1994
• L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Tsao PS, Theilmeier G, Singer AH, Leung LL, Cooke JP. Arterioscler Thromb. 1994; 14 (10): 1529-33
• Identification of SVTCG in thrombospondin as the conformation-dependent, high affinity binding site for its receptor, CD36. Li WX, Howard RJ, Leung LL. J Biol Chem. 1993; 268 (22): 16179-84